Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084591 · ClinicalTrials.gov registry record · Phase 1
Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00084591: Completed Phase 1 study, sponsored by Fox Chase Cancer Center.
NCT00084591 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084591, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) with incorporated boost (an increase in the amount of radiation given during treatment) may cause less damage to normal tissue. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy together with chemotherapy before surgery may shrink the tumor so it can be removed. PURPOSE: This phase I trial is studying the side effects and best dose of neoadjuvant intensity-modulated radiation therapy with incorporated boost when given together with capecitabine in treating patients with locally advanced rectal cancer.
Interventions
- DRUG capecitabine
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-12 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
What the finished NCT00084591 record still lists
NCT00084591 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which capecitabine is the first listed.
NCT00084591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00084591 about?
NCT00084591 is a clinical study titled "Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) with incorporated boost (an increase in the amount of radiation given during treatment) may cause less...
What is the current status of trial NCT00084591?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-12. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00084591?
The interventions under investigation include: capecitabine (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00084591?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia